Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3006400 | 0.87 | IDO1 (0.45) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL12394690 | 0.84 | MEN1 (0.41) | JAK2SUV39H2MEN1KMT2AMMP8 | |
| SCHEMBL1115122 | 0.81 | CA12 (0.47) | KDM4EALDH1A1HDAC1HDAC3HDAC2 | |
| SCHEMBL12394688 | 0.77 | CYP1A2 (0.55) | MEN1KMT2AMMP8MMP3KDM4E | |
| SCHEMBL29481024 | 0.76 | SMN1; SMN2 (0.51) | JAK2SUV39H2MEN1KMT2AMMP8 | |
| SCHEMBL31323267 | 0.75 | HDAC8 (0.51) | JAK2MEN1KMT2AALDH1A1HDAC4 | |
| SCHEMBL13258134 | 0.75 | HDAC8 (0.51) | JAK2MEN1KMT2AALDH1A1HDAC4 | |
| SCHEMBL13258279 | 0.75 | HDAC8 (0.51) | JAK2MEN1KMT2AALDH1A1HDAC4 | |
| SCHEMBL1752669 | 0.73 | TAAR1 (0.55) | JAK2MEN1KMT2AHDAC4HDAC1 | |
| SCHEMBL1752666 | 0.72 | HDAC4 (0.65) | JAK2HDAC4HDAC1HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956295-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-01 | — | — | US | disclosed |
| US-20160324975-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-11-10 | — | — | US | disclosed |
| US-9433683-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2016-09-06 | — | — | US | disclosed |
| US-20160000927-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2016-01-07 | — | — | US | disclosed |
| US-9119883-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2015-09-01 | — | — | US | disclosed |
| US-20150057219-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-02-26 | — | — | US | disclosed |
| US-8877709-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2014-11-04 | — | — | US | disclosed |
| US-8735350-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| US-20140121352-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2014-05-01 | — | — | US | disclosed |
| US-8575102-B2 | Conjugates having a releasable linkage | NEKTAR THERAPEUTICS (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130116175-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2013-05-09 | — | — | US | disclosed |
| US-8343910-B2 | Reversible pegylated drugs | YEDA RESEARCH DEVELOPMENT CO., LTD (IL) | 2013-01-01 | — | — | US | disclosed |
| US-20110190209-A1 | CONJUGATES HAVING A RELEASABLE LINKAGE | NEKTAR THERAPEUTICS (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100041867-A1 | REVERSIBLE PEGYLATED DRUGS | Yeda Reserch and Development Co., Ltd. (IL) | 2010-02-18 | — | — | US | disclosed |
| WO-2010014258-A2 | CONJUGATES HAVING A RELEASABLE LINKAGE | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| US-7585837-B2 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057219-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | JAK2 656/4885SUV39H2 3909/4885MEN1 4429/4885 |
| US-20100041867-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | JAK2 656/4885SUV39H2 3909/4885MEN1 4429/4885 |
| US-20110190209-A1 | CONJUGATES HAVING A RELEASABLE LINKAGE | CD44, GUSB, MSN | JAK2 3515/4885SUV39H2 1451/4885MEN1 1346/4885 |
| US-20140121352-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | JAK2 656/4885SUV39H2 3909/4885MEN1 4429/4885 |
| US-20130116175-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | JAK2 656/4885SUV39H2 3909/4885MEN1 4429/4885 |
| US-20160324975-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | JAK2 656/4885SUV39H2 3909/4885MEN1 4429/4885 |
| US-20160000927-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | JAK2 656/4885SUV39H2 3909/4885MEN1 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.